Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Exubera inhaled insulin: Phase III

In a 6-month Phase III study of 328 Type I diabetes patients, Exubera before meals plus 2 daily insulin injections

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE